CASI pharmaceuticals, Inc.
23 clinical trials · Sponsor
◉ Watch CASI pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma (NCT04758767) | CASI pharmaceuticals, Inc. | 2021-03-22 |
Track CASI pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.